Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANDA: Probacine in Cardiovascular Surgery
NCT04444362Enrolling by invitation
- Sponsor
- Nanjing Medical University
- Start
- Jan 2025
- Primary completion
- Dec 2026
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Randomised, open-label trial of Probacine in cardiovascular disease (CVD) and cardiopulmonary bypass (CPB) (2 arms), sponsored by Nanjing Medical University. Primary endpoint: Acute Gastrointestinal Injury at 14 days. Started Jan 2025; status: enrolling by invitation.
02
Drugs
Probacine
03
Conditions
cardiovascular disease (CVD)cardiopulmonary bypass (CPB)
Beyond the preview
Go deeper on NCT04444362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04444362.